Assessment of the Long-term Safety and Efficacy of Erenumab During Open-label Treatment of Subjects with Chronic Migraine

被引：0

作者：

Tepper, S. J. ^{[1
]}

Ashina, M. ^{[2
]}

Brandes, J. ^{[3
]}

Dolezil, D. ^{[4
]}

Silberstein, S. D. ^{[5
]}

Winner, P. K. ^{[6
]}

Zhang, F. ^{[7
]}

Cheng, S. ^{[7
]}

Mikol, D. D. ^{[7
]}

机构：

[1] Dartmouth Hitchcock Med Ctr, Dept Neurol, Lebanon, NH 03766 USA

[2] Rigshosp Glostrup, Glostrup, Hovedstaden, Denmark

[3] Nashville Neurosci Grp, Nashville, TN USA

[4] Prague Headache Ctr, Prague, Jihocesky Kraj, Czech Republic

[5] Jefferson Headache Ctr, Philadelphia, PA USA

[6] Palm Beach Headache Ctr, Premiere Res Inst, W Palm Beach, FL USA

[7] Amgen Inc, Thousand Oaks, CA 91320 USA

来源：

HEADACHE | 2018年 / 58卷 / 08期

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

PF115LB

引用

页码：1302 / 1303

页数：2

共 50 条

[1] Assessment of the long-term safety and efficacy of erenumab during open-label treatment of subjects with chronic migraine
Tepper, Stewart
Ashina, Messoud
Reuter, Uwe
Brandes, Jan L.
Dolezil, David
Silberstein, Stephen
Winner, Paul
Zhang, Feng
Cheng, Sunfa
Mikol, Daniel
[J]. JOURNAL OF HEADACHE AND PAIN, 2018, 19
[2] Assessment of the Long-Term Safety and Efficancy of Erenumab During Open-Label Treatment of Patients With Chronic Migraine
Tepper, Stewart J.
Ashina, Messoud
Reuter, Uwe
Brandes, Jan L.
Dolezil, David
Silberstein, Stephen
Winner, Paul
Zhang, Feng
Cheng, Sunfa
Mikol, Daniel D.
[J]. NEUROLOGY, 2019, 92 (15)
[3] Long-term efficacy and safety during open-label erenumab treatment in Japanese patients with episodic migraine
Sakai, Fumihiko
Takeshima, Takao
Tatsuoka, Yoshihisa
Hirata, Koichi
Cheng, Sunfa
Numachi, Yotaro
Peng, Cheng
Xue, Fei
Mikol, Daniel D.
[J]. HEADACHE, 2021, 61 (04): : 653 - 661
[4] Assessment of prolonged safety and tolerability of erenumab in migraine patients in a long-term open-label study (APOLLON)
Goebel, Hartmut
Schlegel, Eugen
Jaeger, Kathrin
Ortler, Sonja
Leist, Lea
[J]. JOURNAL OF HEADACHE AND PAIN, 2024, 25 (01):
[5] Long-term safety and efficacy of erenumab in patients with chronic migraine: Results from a 52-week, open-label extension study
Tepper, Stewart J.
Ashina, Messoud
Reuter, Uwe
Brandes, Jan Lewis
Dolezil, David
Silberstein, Stephen D.
Winner, Paul
Zhang, Feng
Cheng, Sunfa
Mikol, Daniel D.
[J]. CEPHALALGIA, 2020, 40 (06) : 543 - 553
[6] Long-term efficacy and safety of erenumab in Japanese patients with episodic and chronic migraine: results from a 28-week open-label treatment period of a randomised trial
Hirata, Koichi
Takeshima, Takao
Sakai, Fumihiko
Numachi, Yotaro
Yoshida, Ryuji
Koukakis, Reija
Hasebe, Miki
Yui, Daishi
Lima, Gabriel Paiva da Silva
Cheng, Sunfa
[J]. BMJ OPEN, 2023, 13 (08):
[7] Long-term efficacy and safety of erenumab in migraine prevention: Results from a 5-year, open-label treatment phase of a randomized clinical trial
Ashina, Messoud
Goadsby, Peter J.
Reuter, Uwe
Silberstein, Stephen
Dodick, David W.
Xue, Fei
Zhang, Feng
Paiva da Silva Lima, Gabriel
Cheng, Sunfa
Mikol, Daniel D.
[J]. EUROPEAN JOURNAL OF NEUROLOGY, 2021, 28 (05) : 1716 - 1725
[8] SUSTAINED EFFICACY AND LONG-TERM SAFETY OF ERENUMAB IN PATIENTS WITH EPISODIC MIGRAINE: RESULTS OF A 5-YEAR, OPEN-LABEL EXTENSION STUDY
Ashina, Messoud
Goadsby, Peter J.
Reuter, Uwe
Silberstein, Stephen
Dodick, David W.
Xue, Fei
Zhang, Feng
Cheng, Sunfa
Chou, Denise E.
Lima, Gabriel Paiva da Silva
[J]. CEPHALALGIA, 2020, 40 : 60 - 61
[9] A multicenter, open-label long-term safety study of rimegepant for the acute treatment of migraine
Croop, Robert
Berman, Gary
Kudrow, David
Mullin, Kathleen
Thiry, Alexandra
Lovegren, Meghan
L'Italien, Gilbert
Lipton, Richard B.
[J]. CEPHALALGIA, 2024, 44 (04)
[10] Sustained Efficacy and Long-term Safety of Erenumab in Patients with Episodic Migraine: 4+Year Results of a 5-year, Open-label Treatment Period
Ashina, Messoud
Goadsby, Peter
Reuter, Uwe
Silberstein, Stephen
Dodick, David
Xue, Fei
Zhang, Feng
Cheng, Sunfa
Mikol, Daniel
[J]. NEUROLOGY, 2020, 94 (15)

← 1 2 3 4 5 →